First Evidence for a Crosstalk Between Mitochondrial and NADPH Oxidase-derived Reactive Oxygen Species in Nitroglycerin-triggered Vascular Dysfunction
Overview
Authors
Affiliations
Chronic nitroglycerin treatment results in development of nitrate tolerance associated with endothelial dysfunction (ED). We sought to clarify how mitochondria- and NADPH oxidase (Nox)-derived reactive oxygen species (ROS) contribute to nitrate tolerance and nitroglycerin-induced ED. Nitrate tolerance was induced by nitroglycerin infusion in male Wistar rats (100 microg/h/4 day) and in C57/Bl6, p47(phox/) and gp91(phox/) mice (50 microg/h/4 day). Protein and mRNA expression of Nox subunits were unaltered by chronic nitroglycerin treatment. Oxidative stress was determined in vascular rings and mitochondrial fractions of nitroglycerin-treated animals by L-012 enhanced chemiluminescence, revealing a dominant role of mitochondria for nitrate tolerance development. Isometric tension studies revealed that genetic deletion or inhibition (apocynin, 0.35 mg/h/4 day) of Nox improved ED, whereas nitrate tolerance was unaltered. Vice versa, nitrate tolerance was attenuated by co-treatment with the respiratory chain complex I inhibitor rotenone (100 microg/h/4 day) or the mitochondrial permeability transition pore blocker cyclosporine A (50 microg/h/4 day). Both compounds improved ED, suggesting a link between mitochondrial and Nox-derived ROS. Mitochondrial respiratory chain-derived ROS are critical for the development of nitrate tolerance, whereas Nox-derived ROS mediate nitrate tolerance-associated ED. This suggests a crosstalk between mitochondrial and Nox-derived ROS with distinct mechanistic effects and sites for pharmacological intervention.
Vascular endothelial cell injury: causes, molecular mechanisms, and treatments.
Xia T, Yu J, Du M, Chen X, Wang C, Li R MedComm (2020). 2025; 6(2):e70057.
PMID: 39931738 PMC: 11809559. DOI: 10.1002/mco2.70057.
Heusch G, Andreadou I, Bell R, Bertero E, Botker H, Davidson S Redox Biol. 2023; 67:102894.
PMID: 37839355 PMC: 10590874. DOI: 10.1016/j.redox.2023.102894.
Henriquez-Olguin C, Meneses-Valdes R, Raun S, Gallero S, Knudsen J, Li Z Redox Biol. 2023; 65:102842.
PMID: 37572454 PMC: 10440567. DOI: 10.1016/j.redox.2023.102842.
Kuntic I, Kuntic M, Oelze M, Stamm P, Karpi A, Kleinert H Pflugers Arch. 2023; 475(7):807-821.
PMID: 37285062 PMC: 10264265. DOI: 10.1007/s00424-023-02825-9.
Diazoxide is a powerful cardioprotectant but is not feasible in a realistic infarct scenario.
Kleinbongard P, Lieder H, Skyschally A, Heusch G Front Cardiovasc Med. 2023; 10:1173462.
PMID: 37153458 PMC: 10154575. DOI: 10.3389/fcvm.2023.1173462.